Eckert & Ziegler acquires the Analytic Instrumentation and Radiochemistry Equipment Business from Bioscan, Inc.
Eckert & Ziegler Strahlen- und Medizintechnik AG has entered into an agreement with Bioscan, Inc., located in Washington, D.C., to acquire its radiopharmaceutical equipment business. The transaction involves both analytical instruments used in quality assurance of radioactive pharmaceuticals and automated radiopharmaceutical synthesis units. Such equipment is used worldwide in the production of radiolabeled molecular imaging agents used in nuclear medicine.
Eckert & Ziegler Radiopharma Board member, Dr. André Heß, explained: "The products we have acquired ideally enhance our developing equipment business and ensure we can offer our customers system solutions for the production and quality assurance of radiopharmaceuticals. By such an investment we are broadening our commitment to the North American market."
"Bioscan has been a leading player in radioanalytic and radiochemistry instrumentation for more than thirty years. Over the past five years, the company has increasingly focused on its fast-growing molecular imaging business", commented Alex Kleinman, Vice President of Marketing and Business Development for Bioscan. "Today's transaction will enable Bioscan to increase investment in its rapidly expanding preclinical imaging product line. We are pleased to be able to entrust our radiopharmaceutical equipment business and the thousands of customers that use Bioscan radioanalytic and radiochemistry instruments every day to a market leader like Eckert & Ziegler."
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
PET imaging with special tracer can detect and diagnose early Alzheimer's disease
Through thick and thin - Decades-old fluid question solved
Microfluidic molecular exchanger helps control therapeutic cell manufacturing
Autonomous synthesis robot uses AI to speed up chemical discovery - Impressive ingenuity
Differentiating amino acids: Foundation for direct sequencing of individual proteins developed
Research under high pressure - Why 3,000 bars are needed to take a comprehensive look at a protein
Oxford Gene Technology and Abcodia form Partnership - Companies Combine Expertise to Advance Biomarkers for the Early Diagnosis of Pancreatic Cancer
Targeting a large family of parasites - Potential drug target is identified
Sigma-Aldrich strengthens position in RNAi and cell-based assays
Watching the production of new proteins in live cells
Focus Diagnostics - First U.S. Laboratory to License Newly Discovered Coronavirus CoV-NL63 From Primagen